Cell Journals publishes BeyondSpring’s new data on mechanism of plinabulin
BeyondSpring announced that Cell Press publications Chem and Cell Reports published new data that sheds light on the mechanism of action of the Company’s lead Phase 3 asset, Plinabulin, being developed in parallel for the treatment of cancer and prevention of chemotherapy-induced neutropenia. October 08, 2019